How semaglutide drives fat loss — and what the evidence actually shows

Step 1, the mechanism: what semaglutide is actually doing inside your body

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases naturally after you eat; it signals to the brain that food has arrived, dials down appetite, and tells the stomach to slow down. Semaglutide mimics that hormone but stays active far longer than the natural version, long enough to sustain those appetite-reducing signals across the whole week between injections.

The result is a consistent reduction in hunger and, crucially, a reduction in the almost-automatic urge to eat between meals. Food cravings ease. Portion sizes tend to fall without active effort. Over weeks, that lower energy intake creates the calorie deficit that leads to fat loss. Semaglutide does not directly 'burn' fat, it changes the environment in which your body makes decisions about food. That framing matters, because it explains both why the medicine works and why lifestyle support (diet quality, protein intake, activity) makes a meaningful difference to how much of the weight lost comes from fat versus lean mass. The NHS patient information page for semaglutide describes this mechanism clearly and is worth reading before you start.

Semaglutide is sold as Wegovy for weight management in the UK. If you want a broader overview of the medicine across its licensed uses, our semaglutide overview page covers the full picture.

Step 2 (the dose escalation: why fat loss builds gradually rather than immediately

Treatment begins at 0.25 mg once weekly) a tolerability dose rather than a therapeutic one. The point of starting low is to let your gut adjust, keeping nausea and digestive discomfort manageable. The dose increases roughly every four weeks: 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg, and finally the standard 2.4 mg maintenance dose. The MHRA approved a 7.2 mg maintenance option in early 2026 for adults with a BMI of 30 or above, supplied initially as three 2.4 mg pens per week and then via a dedicated single-dose pen approved on 14 April 2026.

Because the therapeutic effect builds alongside the dose, noticeable fat loss often becomes clearest from around months two and three, once the maintenance dose is reached. Patience in the escalation phase pays off, the prescriber sets the pace, and pushing ahead faster does not accelerate results, it increases side-effect risk.

Storage is straightforward: keep each pen in the fridge door until you open it, then follow your patient information leaflet for how long it can sit at room temperature before use. Keep the leaflet to hand. Our page on semaglutide and weight loss goes into more detail on what to expect month by month.

Step 3, the evidence: what clinical trials showed about semaglutide fat loss

The headline figure comes from STEP 1, a 68-week randomised trial involving over 1,900 adults with obesity or overweight plus at least one weight-related condition. Participants using semaglutide 2.4 mg alongside lifestyle intervention lost an average of around 15% of their starting body weight, compared with around 2.4% in the placebo group, as published in the New England Journal of Medicine.

At the higher 7.2 mg dose, trials reported average losses of around 20.7% over 72 weeks, narrowing the gap with tirzepatide's results. These are group averages; individual outcomes vary. Factors that influence how much fat someone loses include starting weight, adherence to the dose schedule, diet quality, and activity level. People who want to understand how Wegovy approaches Wegovy fat loss specifically may find our dedicated page useful, alongside our page on semaglutide and belly fat which covers what the data say about where fat reduction tends to occur first.

NICE has recommended semaglutide (as Wegovy) for NHS use under specific criteria (including a maximum treatment duration of two years within a specialist weight management service) as set out in NICE technology appraisal TA875. Private treatment is not subject to the same two-year cap, though the prescriber reviews every repeat order.

Step 4, what fat loss on semaglutide looks and feels like in practice

Most people notice appetite changes within the first few weeks, often before the scales shift noticeably. Meal sizes feel adequate at smaller volumes. The pull toward snacking eases. That changed relationship with food is, for many, the most significant shift, and the one that explains why fat loss tends to continue steadily across months rather than arriving in a single dramatic drop.

Side effects are mostly gastrointestinal: nausea, constipation, loose stools, reflux and fatigue are the most commonly reported. They tend to peak in the days after a dose increase and settle as the body adjusts. Severe or persistent stomach pain should always be assessed by a clinician promptly. Eating smaller, lower-fat meals during the titration phase helps. Our plain-language guide to the semaglutide injection covers the practical side of using the pen week to week.

Semaglutide is not licensed for people under 18, and it is not recommended during pregnancy, breastfeeding, or for anyone actively trying to conceive. The prescriber will discuss your full medical history, including any medicines you already take, before a prescription is issued. If you are considering semaglutide for fat loss and want to understand the cost side, our Wegovy pricing page sets out what private treatment typically involves.